BioSpace News Archive

AVROBIO, Inc today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to investigational AVR-RD-02, a first-in-class gene therapy that uses patients’ own hematopoietic stem cells to treat Gaucher disease, a rare lysosomal disorder that can lead multiorgan pathology, clinical morbidity and early mortality.

Today Reveleer, a healthcare technology company using intelligent automation to empower data-driven healthcare for payers in all lines of business, announced the launch of NLP First Pass for Quality, an Artificial Intelligence (AI)-assisted abstraction solution for health plans and risk-bearing providers nationwide.

LEXEO Therapeutics today announced that the European Commission has granted Orphan Drug Designation to LX1004 for the treatment of CLN2 Batten disease.

joimax ® is continuing its year-over-year double digit growth. Over the past 9 months, joimax ® has grown more than 25% globally and in the United States alone, more than 35%.

HemoShear Therapeutics, Inc. today announced that it will participate in SVB Leerink Biopharma Private Company Connect being held virtually October 26-27.

Accelus, a privately held medical technology company focused on accelerating the adoption of minimally invasive surgery as the standard of care in spine, announced the rapid global expansion and international use of its FlareHawk® Interbody Fusion System.

Aptinyx Inc. today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights.

Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) indications, today announces that the US Food and Drug Administration (FDA) has granted Fast Track designation to its mGluR5 inhibitor basimglurant (NOE-101) for the treatment of trigeminal neuralgia (TN).

Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, will report results for the third quarter ended September 30, 2022, after the market closes on October 26, 2022.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first participant has been dosed in the Phase 2 PENINSULA (Prevention of Illness Due to Influenza A) trial evaluating VIR-2482 for the prevention of illness due to influenza A.